PMID- 36788718
OWN - NLM
STAT- MEDLINE
DCOM- 20230615
LR  - 20230615
IS  - 1527-330X (Electronic)
IS  - 1090-820X (Linking)
VI  - 43
IP  - 7
DP  - 2023 Jun 14
TI  - Facial Dermal Filler Injection and Vaccination: A 12-Year Review of Adverse Event 
      Reporting and Literature Review.
PG  - NP544-NP557
LID - 10.1093/asj/sjad031 [doi]
AB  - BACKGROUND: Following authorization of 2 COVID-19 vaccines in December 2020, 
      media attention increased towards postvaccine adverse events (AEs) in patients 
      with facial dermal filler injections. OBJECTIVES: The purpose of this study was 
      to characterize vaccine-related facial dermal filler AEs by scrutinizing the 
      FDA's Manufacturer and User Facility Device Experience (MAUDE) database. METHODS: 
      The MAUDE database was queried from January 1, 2011 to January 28, 2023 for 
      facial dermal filler medical device reports (MDRs) discussing vaccination-related 
      AEs. A PubMed (National Institutes of Health, Bethesda, MD) literature review on 
      dermal filler AEs was then conducted. Data were analyzed with descriptive 
      statistics. RESULTS: Of 10,637 MDRs identified, 33 were included. There were 25 
      MDRs (75.8%) related to COVID-19 vaccination. Hyaluronic acid-based fillers were 
      described in 31 MDRs (93.9%). AEs were mostly reported within days postinjection 
      (n = 7, 21.2%), but ranged from immediately (n = 2, 6.1%) to months (n = 6, 
      18.2%) postinjection. Most AEs were reported postvaccine (n = 17, 51.5%) vs 
      postfiller (n = 14, 42.4%). In 26 reports (78.8%), AEs occurred at the site of 
      filler injection. Most MDRs described inflammation/swelling (n = 21, 28.0%). The 
      literature review returned 302 articles, of which 14 were included. Only 1 
      article (7.1%) was published in a plastic surgery journal. CONCLUSIONS: Although 
      the pandemic brought attention to COVID-19 vaccine-related facial dermal filler 
      AEs, this study shows a low incidence compared with the millions of vaccine and 
      filler injections administered. Reactions with non-COVID-19 vaccines were also 
      documented. Increased awareness may help providers counsel patients undergoing 
      vaccination and dermal filler implantation.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the 
      Aesthetic Society. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Sun, Alexander H
AU  - Sun AH
FAU - Tiongco, Rafael Felix P
AU  - Tiongco RFP
AUID- ORCID: 0000-0001-9213-5081
FAU - Manahan, Michele A
AU  - Manahan MA
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Aesthet Surg J
JT  - Aesthetic surgery journal
JID - 9707469
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Dermal Fillers)
RN  - 0 (Vaccines)
SB  - IM
CIN - Aesthet Surg J. 2023 Jun 14;43(7):NP558-NP559. PMID: 36797986
MH  - Humans
MH  - *COVID-19/prevention & control
MH  - *COVID-19 Vaccines/adverse effects
MH  - *Dermal Fillers/adverse effects
MH  - Vaccination/adverse effects
MH  - Vaccines
EDAT- 2023/02/16 06:00
MHDA- 2023/06/15 06:42
CRDT- 2023/02/15 01:22
PHST- 2023/06/15 06:42 [medline]
PHST- 2023/02/16 06:00 [pubmed]
PHST- 2023/02/15 01:22 [entrez]
AID - 7036865 [pii]
AID - 10.1093/asj/sjad031 [doi]
PST - ppublish
SO  - Aesthet Surg J. 2023 Jun 14;43(7):NP544-NP557. doi: 10.1093/asj/sjad031.